Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunotargeted Agents Combined With Low-Dose Chemotherapy in Newly Diagnosed Ph+ B-ALL
NCT07840976Phase 2Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Oct 2026
- Primary completion
- May 2028
- Countries
- 1
01
Overview
A Phase 2 trial of olverembatinib, venetoclax, inotuzumab ozogamicin, blinatumomab, CD19-directed chimeric antigen receptor T cells in acute lymphoblastic leukemia (ALL), sponsored by Institute of Hematology and Blood Diseases Hospital. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
olverembatinibvenetoclaxinotuzumab ozogamicinblinatumomabCD19-directed chimeric antigen receptor T cells
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT07840976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07840976.